Single Fiber EMG as an Outcome Measure in Myasthenia Gravis: Results from a Double-Blind, Placebo-Controlled Trial

Journal of Clinical Neurophysiology

Volumn 20, Issue 5, 2003, Pages 382-385

  Meriggioli, Matthew N ^a,b   Rowin, Julie ^a  

^a RUSH UNIVERSITY   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Jitter; Myasthenia gravis; Mycophenolate mofetil; Outcome measure; Single fiber electromyography

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ELECTROMYOGRAM; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MALE; MUSCLE FUNCTION; MYASTHENIA GRAVIS; QUANTITATIVE DIAGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; DOUBLE-BLIND METHOD; ELECTROMYOGRAPHY; HUMANS; MALE; MIDDLE AGED; MUSCLE FIBERS; MYASTHENIA GRAVIS; MYCOPHENOLIC ACID; OUTCOME ASSESSMENT (HEALTH CARE); REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC;

EID: 0347419166     PISSN: 07360258     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004691-200309000-00011     Document Type: Article

References (15)

1. Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci 1998;841:769-72.
2. Bogucki A. Serial SFEMG studies of orbicularis oculi muscle after the first administration of botulinum toxin. Eur J Neurol 1999;6:461-7.
3. Holloway RG, Dick AW. Clinical trial end points: on the road to nowhere? Neurology 2002;58:679-86.
4. Howard JF, Sanders DB. Serial single-fiber EMG studies in myasthenic patients treated with corticosteroids plasma exchange therapy. Muscle Nerve 1981;4:254.
5. Kelloff GJ, Sigman CC, Johnson KM, Boone CW, Greenwald P, Crowell JA, Hawk ET, Doody LA. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 2000;9:127-37.
6. Konishi T, Nishitani H, Matsubara F, Ohta M. Myasthenia gravis: relation between jitter in single-fiber EMG and antibody to acetylcholine receptor. Neurology 1981;31:386-92.
7. Lange DJ. Single fiber electromyography in normal subjects: reproducibility, variability, and technical considerations. Electromyogr Clin Neurophysiol 1992;32:397-402.
8. Massey JM, Sanders DB. Single fiber electromyography in myasthenia gravis during pregnancy. Muscle Nerve 1993;16:458-60.
9. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: A double-blind, placebo-controlled pilot trial. Ann N Y Acad Sci 2003;998:494-9.
10. Sanders DB. Clinical impact of single-fiber electromyography. Muscle Nerve 2002;11:S15-S20.
11. Sanders DB, Howard JF, Johns TR. Single-fiber electromyography in myasthenia gravis. Neurology 1979;29:68-76.
12. Sanders DB, Stalberg EV. AAEM minimonograph #25: single-fiber electromyography. Muscle Nerve 1996;19:1069-83.
13. Sanders DB, Tucker-Lipscomb B, Massey JM. A simple manual muscle test for myasthenia gravis: validation and comparison with the QMG score. Presented at the Xth International Conference on Myasthenia Gravis and Related Disorders, Key Biscayne, FL, May 29, 2002.
14. Straube A, Garner CG, Witt TN. Repeated single fiber recordings do not affect the jitter and fiber density. Electromyogr Clin Neurophysiol 1994;34:387-90.
15. Wingerchuk DM, Noseworthy JH. Randomized controlled trials to assess therapies for multiple sclerosis. Neurology 2002;58:S40-S48.